fda
15 records
FDA Drug Recall: TIROSINT - SOL (levothyroxine sodium) Oral Solution, 200 microgram/mL; 6 pouches
2023-03-01
Class II — Subpotent Drug
View Source
FDA Drug Recall: TIROSINT - SOL (levothyroxine sodium) Oral Solution, 137 microgram/mL; 6 pouches
2023-03-01
Class II — Subpotent Drug
View Source
FDA Drug Recall: TIROSINT - SOL (levothyroxine sodium) Oral Solution, 75 microgram/mL; 6 pouches
2023-03-01
Class II — Subpotent Drug
View Source
FDA Drug Recall: TIROSINT - SOL (levothyroxine sodium) Oral Solution, 150 microgram/mL; 6 pouches
2023-03-01
Class II — Subpotent Drug
View Source
FDA Drug Recall: TIROSINT - SOL (levothyroxine sodium) Oral Solution, 62.5 microgram/mL; 6 pouche
2023-03-01
Class II — Subpotent Drug
View Source
FDA Drug Recall: TIROSINT - SOL (levothyroxine sodium) Oral Solution, 175 microgram/mL; 6 pouche
2023-03-01
Class II — Subpotent Drug
View Source
FDA Drug Recall: TIROSINT - SOL (levothyroxine sodium) Oral Solution, 112 microgram/mL; 6 pouches
2023-03-01
Class II — Subpotent Drug
View Source
FDA Drug Recall: TIROSINT - SOL (levothyroxine sodium) Oral Solution, 37.5 microgram/mL; 6 pouche
2023-03-01
Class II — Subpotent Drug
View Source
FDA Drug Recall: TIROSINT - SOL (levothyroxine sodium) Oral Solution, 125 microgram/mL; 6 pouche
2023-03-01
Class II — Subpotent Drug
View Source
FDA Drug Recall: TIROSINT - SOL (levothyroxine sodium) Oral Solution, 88 microgram/mL; 6 pouches
2023-03-01
Class II — Subpotent Drug
View Source
FDA Drug Recall: TIROSINT - SOL (levothyroxine sodium) Oral Solution, 100 microgram/mL; 6 pouches
2023-03-01
Class II — Subpotent Drug
View Source
FDA Drug Recall: TIROSINT - SOL (levothyroxine sodium) Oral Solution, 13 microgram/mL; 6 pouches
2023-03-01
Class II — Subpotent Drug
View Source
FDA Drug Recall: TIROSINT - SOL (levothyroxine sodium) Oral Solution, 44 microgram/mL; 6 pouches
2023-03-01
Class II — Subpotent Drug
View Source
FDA Drug Recall: TIROSINT - SOL (levothyroxine sodium) Oral Solution, 50 microgram/mL; 6 pouches
2023-03-01
Class II — Subpotent Drug
View Source
FDA Drug Recall: TIROSINT - SOL (levothyroxine sodium) Oral Solution, 25 microgram/mL; 6 pouches
2023-03-01
Class II — Subpotent Drug
View Source
fda_adverse
1 records
FDA AE Manufacturer: IBSA Pharma Inc.
Drug adverse event reporter — Product: LEVOTHYROXINE SODIUM
View Source
Be informed when major changes happen on C.F.A.I. — new data sources, platform updates, critical enforcement alerts
No spam. Only major updates. Unsubscribe anytime.